Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second-Line Erlotinib + Chemotherapy in EGFR-Mutant NSCLC
NCT02098954Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Jul 2014
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Hunan Cancer Hospital. Started Jul 2014; status: recruiting.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02098954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02098954.